The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | In vivo modelling of CLL into Richter’s syndrome
Elisa ten Hacken, PhD, Harvard Medical School, Boston, MA, outlines a study which demonstrated that combinatorial in vivo modelling of chronic lymphocytic leukemia (CLL) loss-of-function mutations using multiplexed CRISPR leads to development of both CLL and Richter’s syndrome (RS). This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
